西格列他钠联合门冬胰岛素30注射液治疗2型糖尿病患者的临床效果与安全性

Clinical efficacy and safety of Chiglitazar Sodium combined with Insulin Aspart 30 Injection in the treatment of patients with diabetes mellitus type 2

目的探讨新型过氧化物酶体增殖物激活受体(PPARs)泛激动剂西格列他钠治疗2型糖尿病的临床效果与安全性。方法选取2022年1月至6月联勤保障部队第九七〇医院威海医疗区收治的68例2型糖尿病患者作为研究对象,按照随机数字表法分为观察组(n=34)和对照组(n=34)。对照组采用门冬胰岛素30注射液治疗,观察组在对照组的基础上联合西格列他钠治疗。比较两组患者治疗前后的胰岛素抵抗指数(HOMA-IR)、胰岛β细胞功能指数(HOMA-β)、体重指数(BMI)、血糖情况[糖化血红蛋白(HbA1c)、空腹血糖(FPG)、餐后2 h血糖(2 h PG)]、PPARs水平及不良反应的差别。结果观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05);观察组的HOMA-IR、HbA1c、FPG、2hPG均低于对照组,差异有统计学意义(P<0.05);观察组的HOMA-β、PPARα、PPARβ、PPARγ水平均高于对照组,差异有统计学意义(P<0.05);两组患者BMI和不良反应比较,差异无统计学意义(P>0.05)。结论西格列他钠可有效改善2型糖尿病患者胰岛功能及胰岛素抵抗,提升PPARs水平,改善血糖控制,提高治疗效果,减少不良反应。

Objective To investigate the clinical efficacy and safety of Chiglitazar Sodium,a new panagonist of peroxisome proliferator-activated receptors(PPARs),in the treatment of diabetes mellitus type 2.Methods A total of 68 patients with diabetes mellitus type 2 admitted to the Weihai Branch of 970th Hospital of PLA Joint Logistics Support Force from January to June 2022 were selected as the study objects,and they were divided into observation group(n=34)and control group(n=34)according to random number table method.The control group was treated with Insulin Aspart 30 Injection,and the observation group was treated with Chiglitazar Sodium on the basis of the control group.The differences of homeostatic model assessment of insulin resistance(HOMA-IR),homeostasis model assessment ofβ-cell function(HOMA-β),body mass index(BMI),blood glucose([glycosylated hemoglobin,HbA1c],[fasting plasma glucose,FPG],[2 h postprandial plasma glucose,2 h PG]),PPARs levels and adverse reactions were compared between the two groups before and after treatment.Results The total effective rate of the observation group was higher than that of the control group,the difference was statistically significant(P<0.05).HOMA-IR,HbA1c,FPG and 2 h PG in observation group were lower than those in control group,the differences were statistically significant(P<0.05).The levels of HOMA-β,PPARα,PPARβand PPARγin observation group were higher than those in control group,the differences were statistically significant(P<0.05).There was no significant difference in BMI and adverse reactions between the two groups(P>0.05).Conclusion Chiglitazar Sodium can effectively improve islet function and insulin resistance in diabetes patients type 2,increase PPARs level,improve blood glucose control,improve treatment effect,and reduce adverse reactions.